We are a passionate, diverse, and focused group of medical researchers, healthcare professionals, and renowned scientific advisors dedicated to transforming the Alzheimer’s disease ecosystem through earlier diagnosis, intervention, and personalized treatment to improve outcomes for people with Alzheimer’s disease.
We understand the undue impact this disease places upon patients, families, caregivers, and the community at large. We are rooted in the belief that with a timely and accurate diagnosis, targeted treatment, education, and the appropriate care and support resources, it is possible for people to live well after an Alzheimer’s disease diagnosis. This is possible only by fundamentally rethinking, and rewriting the current diagnosis, treatment, and management paradigm.
Through our passion, creativity, and perseverance, we will rewrite the Alzheimer’s disease diagnosis, treatment, and management paradigm. We are steadfast in our commitment to improve the lives of those impacted by this disease.
Copyright 2023 ALZpath Inc. All Rights Reserved
Julie Reisetter, MS, RN joined ALZpath in 2022 and is currently the VP, Clinical Solutions. Julie has over 30 years of clinical, administrative and digital product leadership. Her experience includes positions with three of the nation’s leading health systems creating their virtual care solutions, innovation plans and care delivery strategies. She is skilled at cultivating strategic partnerships, managing complex problems, and developing breakthrough solutions that improve patient outcomes and enhance the care experience. Julie has spoken widely on a national level and serves in a variety of advisory and board positions. Her educational background includes a Bachelor of Science in Nursing from the University of Iowa and a Master in Science from the University of California-San Francisco.
Jerre Stead was Executive Chairman and Chief Executive Officer of Clarivate plc from June 2019 until his October 2022 retirement. Jerre served as CEO of Churchill Capital Corp until its May 2019 merger with Clarivate.
Jerre has had a long and very successful career as a public company CEO and Clarivate is the tenth public company in which he has served as CEO and/or Chairman. Over the last two decades, he has created a world leader and one of the fastest-growing companies in the information services sector. Prior to leading Clarivate, he served as Chairman and CEO at IHS Markit, Ltd. and previously as Executive Chairman and CEO at IHS Inc. The other highly successful technology and information companies he has led include Honeywell-Phillips Medical Electronics, Square D, AT&T Global Business Communications Systems, AT&T Global Information Solutions (NCR Corporation), NCR Japan, Legent Corporation and Ingram Micro.
In addition, Jerre has served on 37 corporate boards during his career and received numerous accolades for his work, including the July 2017 Kenneth B. West Lifetime Achievement Award which he received by the National Association of Corporate Directors (NACD) in recognition of his service on corporate and philanthropic boards.
A graduate of the University of Iowa and the Harvard University Advanced Management Program in Switzerland, Jerre earned a bachelor’s degree in business administration. He is chairman of the Banner Alzheimer’s Institute as well as chairman of the board of Garret Evangelical Seminary and he sits on the American Writers Museum and Guideposts boards.
Jeffrey Cummings, MD, ScD, is the Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). Dr. Cummings is globally recognized for his contributions to Alzheimer’s research, drug development, and clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through many awards including the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017), Distinguished Scientist Award of the American Association of Geriatric Psychiatry (2010), Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association (2019), and the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rock Star of Science™.” Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London. Dr. Cummings was formerly Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. He has authored or edited 43 books and published over 800 peer-reviewed papers.
Professor Snyder received his doctorate in clinical neuropsychology and behavioral neuroscience from Michigan State University in 1992, following a residency at Long Island Jewish Medical Center. Dr. Snyder was awarded the 1992 Wilder Penfield Fellowship by the American Epilepsy Society and Epilepsy Foundation of America, and he served as a Clinical Neurosciences Fellow in the NIMH Clinical Research Center for the Study of Schizophrenia at Hillside Hospital (Albert Einstein College of Medicine) in 1992 and 1993.
Dr. Snyder is the Founding Editor-in-Chief for Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (an Alzheimer’s Association open access journal), and he manages a robust research program. His academic interests span across a range of topics in neuropharmacology, neurophysiology, history of neuroscience and research ethics; his clinical interests are currently focused on the topics of aging and dementia. From 1998 through 2005, Dr. Snyder was employed as a scientist, clinician, and director at Pfizer Global Research & Development – Groton Laboratories (Connecticut, USA) – the largest research laboratory of Pfizer Inc. Dr. Snyder was responsible for the identification and development of novel clinical technologies and biomarkers for the CNS therapeutic area at Pfizer. As a Director and Early Clinical Leader at Pfizer, Dr. Snyder led the development of novel compounds for the treatment of schizophrenia and Alzheimer’s disease.
Currently, Dr. Snyder is the Vice President for Research & Economic Development at the University of Rhode Island, where he also serves as a Professor of Biomedical Sciences as well as of Art and Art History (sculpture/wood).
Dr. Reiman is an ALZpath Co-Founder and Advisor. He is also Executive Director of Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Senior Scientist at the Translational Genomics Research Institute, Director of the NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). A psychiatrist and brain imaging researcher by background, his interests include brain imaging, emerging blood-based biomarkers, APOE and genomics research, the unusually early detection and tracking of Alzheimer’s disease, the discovery and accelerated evaluation of Alzheimer’s prevention therapies, and new models of research collaboration and clinical care. He is an author of more than 600 publications, a principal investigator of several large research NIH grants, other research grants, and contracts; a former member of the National Advisory Council on Aging (NIA Council); and a recipient of the Potamkin Prize for his contributions to the study, early detection, and prevention of Alzheimer’s disease.
Dr. Blennow is professor and academic chair in neurochemistry at the University of Gothenburg, and head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital in Gothenburg, Sweden. He has a specialist competency in both general psychiatry and clinical chemistry, and holds the Torsten Söderberg Professorship at the Royal Swedish Academy of Sciences. Dr. Blennow has published more than 1,800 original research papers and review articles in peer-reviewed journals, has an h-index of 161, and his papers have been cited more than 125,000 times.
He is president of the Society for CSF Analysis and Clinical Neurochemistry, head of the Alzheimer’s Association quality control program for cerebrospinal fluid (CSF) biomarkers, and chair of the International Federation of Clinical Chemistry (IFCC) working group for CSF proteins. He has received several scientific awards, including the CINP Award (1992), the IPA Research Award (1993), the Alois Alzheimer Research Award (2001), the ECNP Clinical Research Award (2010), the Henry Wisniewski Lifetime Achievement Award in Alzheimer’s Disease Research (2011), the International Foundation for Research in Alzheimer’s Disease (IFRAD) European Grand Prix for Research (2013), and the Söderberg Prize in Medicine from the Swedish Society of Medicine (2016).
Jeffrey L. Dage, Ph.D. is a Senior Research Professor of Neurology at Indiana University School of Medicine. He holds a secondary appointment in the Department of Medical and Molecular Genetics. He is the co-leader of the genetics biomarker and biosample core of the Indiana Alzheimer’s Research Center and of the Longitudinal Early Onset Alzheimer’s Disease Study. He is the Scientific Director of the National Centralized Repository for Alzheimer’s and Related Dementias (NCRAD). The current focus of his research is the discovery and development of biomarkers to aid in the understanding of neurodegenerative diseases. Prior to joining IUSM, Dr. Dage worked for Eli Lilly and Company for over 20 years where he pioneered the development of assays for measuring phosphorylated tau in blood.
Dr. Oskar Hansson gained his PhD in neurobiology in 2001 and his M.D. in 2005. He became senior consultant in neurology in 2012 at Skåne University Hospital, and full professor of neurology in 2017 at Lund University, Sweden. Oskar Hansson performs internationally recognized clinical and translational research focusing on the early phases of Alzheimer’s and Parkinson’s diseases. His work on biomarkers has led to over 400 original peer-reviewed publications. He heads the prospective and longitudinal Swedish BioFINDER studies (www.biofinder.se), where the research team focuses on the development of optimized diagnostic algorithms for early diagnosis, and also studies the consequences of different brain pathologies on cognitive, neurologic and psychiatric symptoms in healthy individuals and patients with dementia and parkinsonian disorders. Recently, the BioFINDER team has shown that Tau PET imaging can with high accuracy distinguish Alzheimer’s from all other neurodegenerative diseases (JAMA, 2018), predict cognitive decline in cognitively normal individuals (Nature Medicine, 2022), and to detect different subtypes of Alzheimer’s (Nature Medicine 2021). He has also developed and validated blood-based biomarkers for early detection of Alzheimer’s disease (Nature Medicine, 2020; JAMA, 2020, Nature Aging 2021, Nature Medicine 2021, Nature Medicine 2022). He is the co-director of the strategic research area of neuroscience at Lund University, and responsible for research at the Memory Clinic at Skåne University Hospital.
Soeren Mattke (MD, DSc) is a Research Professor of Economics at USC where he directs the USC Brain Health Observatory. The Observatory conducts research into health system preparedness for diagnosing and treating disorders of the central nervous system. It has published reports on 15 countries’ readiness for an Alzheimer’s treatment and numerous papers on the economic, political and societal implications of such a treatment. Prior to joining USC, Dr. Mattke led RAND Health’s private sector practice and worked at the OECD in Paris, in the healthcare practice of Bain & Company in Boston, at Abt Associates, a policy consulting firm in Cambridge, MA, and at Harvard University. He trained as an internist and cardiologist at the University of Munich and received his doctoral degree in health policy at Harvard.
Philip Scheltens, MD, PhD, is Head of the Dementia Fund and partner at EQT Life Sciences. Before joining EQT, Dr. Scheltens worked as founder and Director of the Alzheimer Center at Amsterdam University Medical Center in Amsterdam, The Netherlands. He is an MD (neurology) and holds a PhD in Medicine from the VU University Amsterdam and is currently Emeritus Professor of Neurology at Amsterdam University Medical Centers.
Sterling Johnson, PhD is the Jean R. Finley Professor of Geriatrics and Dementia in the University of Wisconsin School of Medicine and Public Health where he has worked since 2002. A clinical neuropsychologist, he is the Associate Director and the Biomarker Core leader of the Wisconsin Alzheimer’s Disease Research Center. He is also the principal investigator of the Wisconsin Registry for Alzheimer’s Prevention (WRAP) which is a long-running observational longitudinal cohort study of 1700 adults who are enriched for risk of Alzheimer’s Disease due to parental family history. Johnson’s lab is interested in longitudinal brain changes in preclinical AD that define its window, and in disambiguating the brain and cognitive changes that take place in AD from normal aging, and from other pathologies. His lab is also studying ways of detecting multi-etiology causes of cognitive impairment. Dr. Johnson’s research has been continuously funded by the NIH since 1997. He has authored or coauthored over 360 peer reviewed publications.